[
    [
        {
            "time": "2018-04-18",
            "original_text": "明日最具投资机会六大牛股一览（2018年4月18日）",
            "features": {
                "keywords": [
                    "投资机会",
                    "牛股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "明日最具投资机会六大牛股一览（2018年4月18日）",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "[买入-A评级]恒瑞医药(600276)动态分析：业绩符合预期 国内外双线布局将助力公司进一步成长",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩",
                    "国内外双线布局"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入-A评级]恒瑞医药(600276)动态分析：业绩符合预期 国内外双线布局将助力公司进一步成长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "33亿外资抄底！深股通资金流入创开通以来单日新高",
            "features": {
                "keywords": [
                    "外资抄底",
                    "深股通",
                    "资金流入"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "33亿外资抄底！深股通资金流入创开通以来单日新高",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "817家公司现国家队身影，白马股分歧，创蓝筹受青睐",
            "features": {
                "keywords": [
                    "国家队",
                    "白马股",
                    "创蓝筹"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "817家公司现国家队身影，白马股分歧，创蓝筹受青睐",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "抗癌药零关税 急需药加快进医保 四股可以持续关注",
            "features": {
                "keywords": [
                    "抗癌药",
                    "零关税",
                    "急需药",
                    "医保"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "抗癌药零关税 急需药加快进医保 四股可以持续关注",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "[买入评级]恒瑞医药(600276)年报点评：业绩分析业绩高于预期;18年关注新上市产品",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "年报",
                    "业绩高于预期",
                    "新上市产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]恒瑞医药(600276)年报点评：业绩分析业绩高于预期;18年关注新上市产品",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "【陆股通交易追踪】陆股通逆势净流入6.88亿元 海康威视等电子股遭抛售",
            "features": {
                "keywords": [
                    "陆股通",
                    "净流入",
                    "海康威视",
                    "电子股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "电子"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【陆股通交易追踪】陆股通逆势净流入6.88亿元 海康威视等电子股遭抛售",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "创新药步入收获期 国际化战略稳步推进",
            "features": {
                "keywords": [
                    "创新药",
                    "国际化战略"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创新药步入收获期 国际化战略稳步推进",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "医药板块大幅回调 风险还是机会",
            "features": {
                "keywords": [
                    "医药板块",
                    "回调",
                    "风险",
                    "机会"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药板块大幅回调 风险还是机会",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "恒瑞医药2017年年报点评:收入增速超预期,重磅新药将陆续上市",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "年报",
                    "收入增速超预期",
                    "重磅新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药2017年年报点评:收入增速超预期,重磅新药将陆续上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]